IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1642		
Martin Leonard Ashdown	Confirmation No.: 8112		
Serial No.: 10/576,981) Examiner: Mark Halvorson		
Filed: March 2, 2007)		
Atty. File No.: 5517-18	SUPPLEMENTAL INFORMATION DISCLOSURE		
Entitled: "Method of Therapy"	STATEMENT		
) Electronically Submitted		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
Dear Sir:			
The references cited on attached Form PTO-	1449 are being called to the attention		
of the Examiner.			
Copies of the cited non-patent and/or foreign	Copies of the cited non-patent and/or foreign references are enclosed herewith.		
Copies of the cited U.S. patents and/or patent	applications are enclosed herewith.		
Copies of the cited U.S. patents/patent application publications are not enclosed in			
accordance with 37 C.F.R. § 1.98(a).			
Copies of the cited references are not enclosed, in accordance with 37 C.F.R.			
§ 1.98(d), because the references were cited by or submitted to the U.S. Patent and			
Trademark Office in prior application Serial No	filed,		
which is relied upon for an earlier filing date under 35 U.S.C. § 120.			
To the best of applicants' belief, the pertiner	ice of the foreign-language references		
are believed to be summarized in the attached En	glish abstracts and/or in the figures,		
although applicants do not necessarily vouch for the	accuracy of the translation.		
Examiner's attention is drawn to the following	g related applications:		
Serial No filed (Attorney Ref. No		
Serial No filed (Attorney Ref. No		
Other:			
Submission of the above information is not in	tended as an admission that any item		
is citable under the statutes or rules to support a rejection, that any item disclosed			
represents analogous out, or that those skilled in the a	rt would refer to or recognize the		

pertinence of any reference without the benefit of hindsight, nor should an inference be

drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

37 CFR 1.37(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfied by one of the following conditions ("X" indicates satisfaction): Within three anoths of the date of a national application other than a continued prosecution application under 37 CFR 1.33(d), or Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application, or Before the mailing date of a first Office Action on the merits, or Before the mailing of a first Office action after the filling of a request for continued examination under 37 CFR 1.114. Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.
37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of any one of the following conditions: (1) a final action under 37 CFR, 1.131, or (2) a notice of allowance under 37 CFR, 1.311, or (3) an action that otherwise closer prosecution in the application. This Information Disclosure Statement is accompanied by: A criffication (below) as specified by 37 CFR, 1.97(c). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 CFR, 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.
37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(e). This information Disclosure Statement includes a Certification (below) as specified by 37 CFR 1.97(e) AND Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$18,000 under 37 CFR 1.17(p). Please credit any overpayment to charge any undersyment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.

	Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)
	The undersigned certifies that: Bach item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1). A copy of the communication from the foreign patent office is enclosed.
	OR
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(e) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).
	Respectfully submitted,
	SHERIDAN ROSS P.C.
Date:	By: Color D. Tower Ph.D. Robert D. Traver Ph.D. Reg. No. 47999 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141 (303) 863-9700

Date: 2/ 1/0V 20//